A Pilot Study of Mitomycin, Ifosfamide and Cisplatin as Outpatient Combination Chemotherapy for Advanced Non-Small Cell Lung Cancer

1991 ◽  
Vol 77 (6) ◽  
pp. 511-513 ◽  
Author(s):  
Gabriella Lucia Mariani ◽  
Maria Cristina Pennucci ◽  
Gianfranco Addamo ◽  
Marco Venturini ◽  
Andrea Ardizzoni ◽  
...  
Keyword(s):  
Response Rate ◽  
Chemotherapy Regimen ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Outpatient Basis ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Lost To Follow Up

Twenty-one patients with advanced stage, non-small-cell lung carcinoma were treated with a chemotherapy regimen including: mitomycin (6 mg/m2), ifosfamide (3 g/m2), cisplatin (80 mg/m2). The regimen was administered on an outpatient basis. Two patients were lost to follow-up. Among the 29 patients evaluable for response we registered a response rate of 36.8 %; 36.8% of patients had stable disease, and 15.7 % progressed during treatment. Median duration was 8.7 months and median survival was 11 months. Toxicity was low and easily manageable on an outpatient basis.

Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients

Lung Cancer ◽  
2008 ◽  
Vol 61 (2) ◽  
pp. 170-176 ◽  
Author(s):  
Paal Fr Brunsvig ◽  
Kjersti Flatmark ◽  
Steinar Aamdal ◽  
Hanne Høifødt ◽  
Hang Le ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Bone Marrow Micrometastases

AN AUDIT OF LUNG CARCINOMAS AT A TERTIARY REFERRAL CENTRE

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Anshita Dubey ◽  
Meenal Hastak ◽  
Bijal Kulkarni ◽  
Nevitha Athikari ◽  
Rajesh Mistry
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Generic Diagnosis ◽  
Advanced Stage ◽  
Histological Subtype ◽  
Small Cell Lung ◽  
Significant Treatment ◽  
Cell Lung Carcinoma ◽  
Lung Carcinomas

A generic diagnosis of ‘small cell or non-small cell carcinoma’ was sufficient in the past when there was no clinical demand for sub classification as it had no impact on therapy. Patients with advanced stage non-small cell lung carcinoma who received chemotherapy were typically treated with a ‘platinum doublet’ of cisplatin plus gemcitabine irrespective of histological subtype. At present, in contrast, sub classification of non-small cell lung carcinoma has significant treatment implications, especially for advanced stage tumors for which chemotherapy or targeted therapy is being considered. Consequently, pathologists are asked to subtype the tumor. The demand for sub typing is driven by oncologists, who now have several new targeted therapies, the efficacy of which varies by histological subtype. In view of demand of sub typing of lung carcinomas as well as the guidelines given by WHO 2015 classification which emphasises the importance of a separate classification for biopsies and cytology on one side and the resection specimen on the other, we have taken up this study. Keywords: Lung carcinoma, classification, core biopsies, immunohistochemistry

8. Post-surgical follow-up for non-small cell lung carcinoma: should we change our practice?

2015 ◽  
Vol 41 (11) ◽  
pp. S263-S264 ◽  
Author(s):  
Fahad Fahad ◽  
Mohammed Haris ◽  
Imran Hussain ◽  
Shilajit Ghosh
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

Reevaluation of the Usefulness of Systematic Bone Scanning in Initial Staging and follow-up of Small Cell Lung Carcinoma, Taking into Account the Serum Levels of Neuron-Specific Enolase

1997 ◽  
Vol 12 (4) ◽  
pp. 148-153 ◽  
Author(s):  
V. Gendreau ◽  
F. Montravers ◽  
C. Philippe ◽  
J.N. Talbot
Keyword(s):  
Bone Metastases ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
False Negative ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Initial Staging

The prescription of bone scans (BS) in the initial staging and follow-up of small cell lung carcinoma (SCLC) is a traditional attitude. The availability of the serum neuron-specific enolase (NSE) assay and budget limitations led us to evaluate retrospectively, in 57 patients, the consequences of a more selective attitude, namely to perform BS only in those patients with abnormal serum NSE levels. Both BS and NSE assays were performed in 47 patients referred for initial staging of SCLC; NSE levels were normal in 8 but in 2 of these cases (25%) secondary bone localizations with great clinical significance were discovered at BS. During follow-up, 59 BS were performed in conjunction with NSE assays; 45 NSE levels were in the normal range whereas 17 (38%) corresponding BS were suggestive of bone metastases. In conclusion, due to the frequent occurrence of false-negative results in patients with bone metastases, serum NSE levels proved to be useless in the selection for BS of patients suffering from SCLC.

scholarly journals Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1152
Author(s):  
Diego Cortinovis ◽  
Paolo Bidoli ◽  
Stefania Canova ◽  
Francesca Colonese ◽  
Maria Gemelli ◽  
...  
Keyword(s):  
Response Rate ◽  
Small Cell Lung Carcinoma ◽  
Survival Rates ◽  
High Response Rate ◽  
Small Cell ◽  
Cytotoxic Agents ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Chemotherapy Drugs ◽  
Chemotherapy Agents

Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum–etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.

scholarly journals Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma patients: a cohort study at a single institute

2019 ◽  
Author(s):  
Yanjie Zhao ◽  
Feng Shi ◽  
Quan Zhou ◽  
Yuchen Li ◽  
Jiangping Wu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Prognostic Significance ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Ki 67 ◽  
Cell Lung Carcinoma ◽  
Expression Status

Abstract Background This study aimed to investigate the prognostic effect of PD-L1 on Chinese non-small cell lung carcinoma patients.Methods A retrospective cohort study was conducted and consecutively recruited 97 patients with non-small cell lung carcinoma. The expression status of PD-1, PD-L1, p53 and Ki-67 was detected by immunohistochemistry. Kaplan-Meier survival curve with log-rank test was used to estimate survival. Cox-Hazard Proportion regression model was used to estimate the hazard ratio and 95% confidence intervalResults The median tumor size was 3.5 cm and 2.0 cm among patients with positive and negative PD-L1 expression, respectively (p<0.001). The proportion of patients with positive and negative PD-L1 expression having nerve invasion was 26.3% and 5.0% (p<0.01). 47.4% patients with positive PD-L1 expression had blood vessel invasion compared with 20.0% patients with negative PD-L1 expression (p<0.01). 64.9% patients with positive PD-L1 expression had lymph node metastasis compared with 27.5% patients with negative PD-L1 expression (p<0.001). Patients with positive PD-L1 expression were more likely to be in advanced stage (p<0.001) and had higher Ki-67 index (p<0.01). PD-L1 expression status did not show any significant association with DFS or OS. However among advanced patients, HR of PD-L1 expression was 4.13 (95%CI 1.06, 16.12).Conclusions Positive PD-L1 expression is associated with poorer prognosis in advanced stage patients. Compare to patients with negative expression, patients with positive PD-L1 expression had more aggressive pathological features. Further prospective studies are needed to confirm the results.

Rapid Arc-SBRT: Non-invasive immune adjuvant for advanced stage Non-Small Cell Lung Carcinoma

2021 ◽  
Vol 21 ◽  
Author(s):  
Arun Chairmadurai ◽  
Sandeep K. Jain ◽  
Aklank Jain ◽  
Hridayesh Prakash
Keyword(s):  
Lung Carcinoma ◽  
Early Stage ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Normal Tissues ◽  
Metastatic Lesions ◽  
Immune Adjuvant

: In conjunction with Radio-chemotherapy, pulmonary resection is recommended for early-stage Non-small-cell lung carcinoma but not for advanced-stage NSCLC patients with having high-grade metastatic lesions. In these cases, Rapid Arc-Stereotactic body radiotherapy (Ra-SBRT) technique offers a therapeutic advantage by delivering focal irradiation to metastatic lung lesions and reduces the bystander toxicity to normal tissues. We have previously demonstrated that Ra-SBRT ablates metastatic lesions and induces tumor immune rejection of metastatic tumors by promoting in situ programming of M2 TAM towards M1-TAM and infiltration of Siglec-8+ Eosinophils. Most interestingly, Ra SBRT has very low abscopal impact and spares normal tissues, which are the significant limitations with conventional radiotherapy. In view of this and Immune adjuvant potential of Ra SBRT, it promotes normalization of aberrant vasculature and inhibits the metastatic potential of NSCLC lesions. In view of this we here propose that Ra-SBRT indeed represents an immunogenic approach for the effective management of advanced-stage NSCLC.

Sign in / Sign up

Export Citation Format

Share Document